Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Drug companies 'not happy' that drug prices 'are going down,' Trump tweets » 10:00
08/13/20
08/13
10:00
08/13/20
10:00
JNJ

Johnson & Johnson

$148.16 /

-1.5 (-1.00%)

, LLY

Eli Lilly

$151.07 /

-0.04 (-0.03%)

, MRK

Merck

$82.53 /

-0.19 (-0.23%)

, PFE

Pfizer

$38.03 /

-0.31 (-0.81%)

, SNY

Sanofi

$51.33 /

-0.55 (-1.06%)

, AZN

AstraZeneca

$56.22 /

+0.37 (+0.66%)

, GSK

GlaxoSmithKline

$41.37 /

+0.1878 (+0.46%)

, NVS

Novartis

$85.50 /

+0.575 (+0.68%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$63.19 /

-0.44 (-0.69%)

President Donald Trump…

President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$82.53 /

-0.19 (-0.23%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.03 /

-0.31 (-0.81%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

08/10/20 SVB Leerink
Principia Biopharma price target raised to $112 from $80 at SVB Leerink
07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

08/12/20 UBS
GlaxoSmithKline price target lowered to 1,800 GBp from 1,920 GBp at UBS
07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
NVS Novartis
$85.50 /

+0.575 (+0.68%)

08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

Yesterday
Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 11:44
08/12/20
08/12
11:44
08/12/20
11:44
PFE

Pfizer

$38.34 /

+0.54 (+1.43%)

, MMA

Municipal Mortgage

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$57.12 /

+1.96 (+3.55%)

, LLY

Eli Lilly

$152.02 /

+1.41 (+0.94%)

Large Cap & Biopharma…

Large Cap & Biopharma Analysts Chen & Kim, along with Key Opinion Leader Dr. Robert Kruse, of Johns Hopkins School of Medicine, discuss Pfizer vs Moderna's COVID-19 vaccine, as well as other leading vaccines in development including AstraZeneca, Eli Lilly, Oxford, on an Analyst/Industry conference call to be held on August 18 at 1 pm.

ShowHide Related Items >><<
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
MMA Municipal Mortgage
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

Hot Stocks
Nektar, Vaccibody AS: First patient dosed in Phase 1/2a study of VB10.NEO/bempeg » 08:06
08/12/20
08/12
08:06
08/12/20
08:06
NKTR

Nektar

$20.39 /

-0.96 (-4.50%)

Vaccibody AS and Nektar…

Vaccibody AS and Nektar Therapeutics announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar's CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck.

ShowHide Related Items >><<
NKTR Nektar
$20.39 /

-0.96 (-4.50%)

NKTR Nektar
$20.39 /

-0.96 (-4.50%)

06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
05/12/20 H.C. Wainwright
Nektar price target lowered to $26 from $32 at H.C. Wainwright
04/22/20 Benchmark
Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma
04/22/20 Benchmark
Nektar initiated with a Buy at Benchmark
NKTR Nektar
$20.39 /

-0.96 (-4.50%)

NKTR Nektar
$20.39 /

-0.96 (-4.50%)

Monday
Hot Stocks
Pieris Pharmaceuticals, Eli Lilly enter into clinical trial collaboration » 06:55
08/10/20
08/10
06:55
08/10/20
06:55
PIRS

Pieris Pharmaceuticals

$2.68 /

-0.06 (-2.19%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

Pieris Pharmaceuticals…

Pieris Pharmaceuticals said in a release, "Pieris Pharmaceuticals (PIRS) announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a VEGFR2 antagonist FDA-approved for multiple types of solid tumors, and paclitaxel for the second-line treatment of patients with HER2-positive gastric cancer in a phase 2 study. Under the terms of the agreement, Lilly will supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year."

ShowHide Related Items >><<
PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

Hot Stocks
Pieris Pharmaceuticals, Eli Lilly enter clinical trial collaboration » 06:37
08/10/20
08/10
06:37
08/10/20
06:37
PIRS

Pieris Pharmaceuticals

$2.68 /

-0.06 (-2.19%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

Pieris Pharmaceuticals…

Pieris Pharmaceuticals (PIRS) announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a VEGFR2 antagonist FDA-approved for multiple types of solid tumors, and paclitaxel for the second-line treatment of patients with HER2-positive gastric cancer in a phase 2 study. Under the terms of the agreement, Lilly will supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year.

ShowHide Related Items >><<
PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.06 (-2.19%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

Sunday
Hot Stocks
Innovent, Lilly announce interim analysis data from ORIENT-11 » 15:28
08/09/20
08/09
15:28
08/09/20
15:28
LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

Innovent Biologics…

Innovent Biologics announced with Eli Lilly that interim analysis data from ORIENT-11 were released in an oral presentation at the IASLC World Conference on Lung Cancer 2020 Virtual Presidential Symposium. This trial was conducted to assess the efficacy of TYVYT in combination with ALIMTA and platinum chemotherapy as a first-line treatment in people with nonsquamous non-small cell lung cancer without sensitive EGFR mutation or ALK rearrangement. ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT or placebo in combination with ALIMTA and platinum chemotherapy as a first-line treatment for advanced or recurrent nsqNSCLC without sensitizing EGFR mutations or ALK rearrangements. Based on the interim analysis conducted by the Independent Data Monitoring Committee, TYVYT in combination with ALIMTA and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo in combination with ALIMTA and platinum chemotherapy, which met the pre-defined efficacy criteria. After a median follow up of 8.9 months, the median PFS of the sintilimab combination and the placebo combination assessed by the Independent Radiographic Review Committee was 8.9 months and 5.0 months, respectively. The median overall survival was not reached in both groups, but OS showed an improvement favoring the sintilimab combination. Confirmed objective response rate was improved from 29.8% to 51.9%, and the sintilimab combination showed a shorter time to response. The safety profile was consistent with previously reported sintilimab studies, and no new safety signals were identified. National Medical Products Administration of China has accepted the supplemental New Drug Application for this indication.

ShowHide Related Items >><<
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 07:32
08/08/20
08/08
07:32
08/08/20
07:32
TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.45 /

-3.87 (-1.79%)

, AZN

AstraZeneca

$55.40 /

-0.8 (-1.42%)

, BMY

Bristol-Myers

$61.03 /

-0.27 (-0.44%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

, GSK

GlaxoSmithKline

$40.79 /

-0.185 (-0.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, KODK

Eastman Kodak

$14.88 /

-1.195 (-7.43%)

, AA

Alcoa

$14.67 /

-0.22 (-1.48%)

, CENX

Century Aluminum

$10.53 /

-0.06 (-0.57%)

, KALU

Kaiser Aluminum

$66.81 /

+0.49 (+0.74%)

, ARNC

Arconic

$19.94 /

-0.395 (-1.94%)

, FB

Facebook

$268.52 /

+3.295 (+1.24%)

, TWTR

Twitter

$37.14 /

-0.55 (-1.46%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

07/16/20 B. Riley FBR
Alcoa price target raised to $11 from $9 at B. Riley FBR
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

06/25/20 BMO Capital
Century Aluminum downgraded to Market Perform from Outperform at BMO Capital
06/09/20 B. Riley FBR
B. Riley FBR downgrades Contura Energy after liquidity stress test
03/24/20 B. Riley FBR
Century Aluminum downgraded to Neutral from Buy at B. Riley FBR
12/20/19 B. Riley FBR
Alcoa price target lowered to $25 from $28 at B. Riley FBR
KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

01/16/20 Benchmark
Kaiser Aluminum initiated with a Hold at Benchmark
ARNC Arconic
$19.94 /

-0.395 (-1.94%)

05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
FB Facebook
$268.52 /

+3.295 (+1.24%)

08/10/20 Truist
Trade Desk price target raised to $450 from $250 at Truist
08/10/20 Morgan Stanley
Pinterest upgraded to Overweight on social shopping trend at Morgan Stanley
08/10/20 Mizuho
Facebook price target raised to $315 from $285 at Mizuho
08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

Over a week ago
Earnings
Nektar reports Q2 EPS (45c), consensus (68c) » 16:56
08/06/20
08/06
16:56
08/06/20
16:56
NKTR

Nektar

$21.52 /

-0.27 (-1.24%)

Reports Q2 revenue…

Reports Q2 revenue $48.8M, consensus $22.8M.

ShowHide Related Items >><<
NKTR Nektar
$21.52 /

-0.27 (-1.24%)

NKTR Nektar
$21.52 /

-0.27 (-1.24%)

06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
05/12/20 H.C. Wainwright
Nektar price target lowered to $26 from $32 at H.C. Wainwright
04/22/20 Benchmark
Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma
04/22/20 Benchmark
Nektar initiated with a Buy at Benchmark
NKTR Nektar
$21.52 /

-0.27 (-1.24%)

NKTR Nektar
$21.52 /

-0.27 (-1.24%)

Periodicals
Trump to order government to buy certain drugs from U.S., USA Today says » 10:12
08/06/20
08/06
10:12
08/06/20
10:12
JNJ

Johnson & Johnson

$148.29 /

-0.1 (-0.07%)

, LLY

Eli Lilly

$154.75 /

+0.36 (+0.23%)

, MRK

Merck

$81.48 /

-0.13 (-0.16%)

, PFE

Pfizer

$38.73 /

+0.28 (+0.73%)

, SNY

Sanofi

$51.41 /

-0.27 (-0.52%)

, AZN

AstraZeneca

$56.22 /

+0.3 (+0.54%)

, GSK

GlaxoSmithKline

$41.04 /

-0.17 (-0.41%)

, NVS

Novartis

$83.51 /

+0.07 (+0.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.67 /

+1.98 (+3.32%)

President Donald Trump…

President Donald Trump will sign an executive order mandating the federal government to buy certain drugs from U.S. manufacturers rather than foreign companies, USA Today's Michael Collins reports, citing officials. The order, which will be signed at Whirlpool's (WHR) manufacturing facility in Ohio, requires the government to develop a list of "essential" medicines and purchase them as well as other medical supplies from the U.S. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$81.48 /

-0.13 (-0.16%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.73 /

+0.28 (+0.73%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
NVS Novartis
$83.51 /

+0.07 (+0.08%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 17:00
08/03/20
08/03
17:00
08/03/20
17:00
MSFT

Microsoft

$216.60 /

+11.605 (+5.66%)

, KSU

Kansas City Southern

$176.59 /

+4.75 (+2.76%)

, VAR

Varian

$174.10 /

+31.655 (+22.22%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, MPC

Marathon Petroleum

$38.56 /

+0.32 (+0.84%)

, ADT

ADT Inc.

$13.42 /

+4.81 (+55.87%)

, GOOG

Alphabet

$1,472.96 /

-9.495 (-0.64%)

, GOOGL

Alphabet Class A

$1,482.78 /

-4.91 (-0.33%)

, LLY

Eli Lilly

$152.83 /

+2.59 (+1.72%)

, TSN

Tyson Foods

$62.41 /

+1.01 (+1.64%)

, CLX

Clorox

$231.99 /

-4.21 (-1.78%)

, JCAP

Jernigan Capital

$17.16 /

+3.21 (+23.01%)

, CODX

Co-Diagnostics

$30.81 /

+6.84 (+28.54%)

, KODK

Eastman Kodak

$14.80 /

-7.5 (-33.63%)

, ALRM

Alarm.com

$58.33 /

-11.51 (-16.48%)

The major averages in the…

Open Full Text

ShowHide Related Items >><<
VAR Varian
$174.10 /

+31.655 (+22.22%)

TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

KODK Eastman Kodak
$14.80 /

-7.5 (-33.63%)

JCAP Jernigan Capital
$17.16 /

+3.21 (+23.01%)

GOOG Alphabet
$1,472.96 /

-9.495 (-0.64%)

CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

CLX Clorox
$231.99 /

-4.21 (-1.78%)

ALRM Alarm.com
$58.33 /

-11.51 (-16.48%)

ADT ADT Inc.
$13.42 /

+4.81 (+55.87%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

08/03/20 Stephens
Stephens sees high odds of Kansas City Southern receiving takeover bid
08/03/20 JPMorgan
JPMorgan upgrades Kansas City Southern, sees 'floor' from potential bid
08/03/20 Citi
Kansas City Southern buyout price needs be way higher than $21B, says Citi
08/03/20 JPMorgan
Kansas City Southern upgraded to Neutral from Underweight at JPMorgan
VAR Varian
$174.10 /

+31.655 (+22.22%)

08/03/20 Deutsche Bank
Siemens Healthineers Hold rating reaffirmed at Deutsche Bank
08/03/20 Citi
Siemens Healthineers had 'clear' rational to acquire Varian, says Citi
08/03/20 Jefferies
Jefferies sees room for potentially higher bid for Varian
08/03/20 BTIG
Varian price target raised to $177.50 from $133 at BTIG
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

08/04/20 AlphaValue
Siemens Healthineers downgraded to Sell from Reduce at AlphaValue
08/04/20 DZ Bank
Siemens Healthineers downgraded to Hold from Buy at DZ Bank
MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

08/04/20 Tudor Pickering
Marathon Petroleum downgraded to Sell from Buy at Tudor Pickering
08/03/20 Morgan Stanley
Marathon sale of Speedway for $21B a 'positive outcome,' says Morgan Stanley
07/15/20 Morgan Stanley
MPLX downgraded to Equal Weight from Overweight at Morgan Stanley
05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
ADT ADT Inc.
$13.42 /

+4.81 (+55.87%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
GOOG Alphabet
$1,472.96 /

-9.495 (-0.64%)

08/03/20 Credit Suisse
ADT Inc. price target raised to $8.70 from $7 at Credit Suisse
GOOGL Alphabet Class A
$1,482.78 /

-4.91 (-0.33%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

07/28/20 Seaport Global
Tyson Foods initiated with a Neutral at Seaport Global
06/10/20 Credit Suisse
Tyson Foods price target raised to $75 from $70 at Credit Suisse
06/04/20
Fly Intel: Top five analyst upgrades
06/04/20 BofA
BofA cuts Pilgrim's Pride, Sanderson Farms targets after price fixing indictment
CLX Clorox
$231.99 /

-4.21 (-1.78%)

08/04/20 DA Davidson
Clorox price target raised to $269 from $256 at DA Davidson
08/04/20 Credit Suisse
Clorox price target raised to $200 from $185 at Credit Suisse
07/27/20 Deutsche Bank
Clorox price target raised to $223 from $174 at Deutsche Bank
07/16/20 JPMorgan
Clorox price target raised to $235 from $203 at JPMorgan
JCAP Jernigan Capital
$17.16 /

+3.21 (+23.01%)

08/03/20 Baird
Jernigan Capital downgraded to Neutral from Outperform at Baird
04/23/20 B. Riley FBR
Jernigan Capital price target lowered to $20 from $26 at B. Riley FBR
08/05/19 Raymond James
Jernigan Capital risk/reward profile more balanced, says Raymond James
08/05/19 Raymond James
Jernigan Capital downgraded to Market Perform from Outperform at Raymond James
CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/18/20 H.C. Wainwright
Co-Diagnostics price target raised to $35 from $20 at H.C. Wainwright
03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
KODK Eastman Kodak
$14.80 /

-7.5 (-33.63%)

ALRM Alarm.com
$58.33 /

-11.51 (-16.48%)

08/03/20 Raymond James
Raymond James sees little near-term impact beyond hardware on Alarm.com from ADT
07/15/20 Northland
Alarm.com price target raised to $72 from $58 at Northland
VAR Varian
$174.10 /

+31.655 (+22.22%)

TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

JCAP Jernigan Capital
$17.16 /

+3.21 (+23.01%)

GOOG Alphabet
$1,472.96 /

-9.495 (-0.64%)

CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

CLX Clorox
$231.99 /

-4.21 (-1.78%)

ALRM Alarm.com
$58.33 /

-11.51 (-16.48%)

ADT ADT Inc.
$13.42 /

+4.81 (+55.87%)

  • 20
    May
TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

KODK Eastman Kodak
$14.80 /

-7.5 (-33.63%)

GOOG Alphabet
$1,472.96 /

-9.495 (-0.64%)

CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

CLX Clorox
$231.99 /

-4.21 (-1.78%)

VAR Varian
$174.10 /

+31.655 (+22.22%)

TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

KODK Eastman Kodak
$14.80 /

-7.5 (-33.63%)

CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

CLX Clorox
$231.99 /

-4.21 (-1.78%)

ALRM Alarm.com
$58.33 /

-11.51 (-16.48%)

VAR Varian
$174.10 /

+31.655 (+22.22%)

TSN Tyson Foods
$62.41 /

+1.01 (+1.64%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

MPC Marathon Petroleum
$38.56 /

+0.32 (+0.84%)

LLY Eli Lilly
$152.83 /

+2.59 (+1.72%)

KSU Kansas City Southern
$176.59 /

+4.75 (+2.76%)

KODK Eastman Kodak
$14.80 /

-7.5 (-33.63%)

CODX Co-Diagnostics
$30.81 /

+6.84 (+28.54%)

CLX Clorox
$231.99 /

-4.21 (-1.78%)

ADT ADT Inc.
$13.42 /

+4.81 (+55.87%)

MSFT Microsoft
$216.60 /

+11.605 (+5.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.